Investor Relations

We are a clinical-stage biopharmaceutical company focused on metabolic and endocrine disorders. We improve compliance, absorption, and more with our proprietary drug delivery technology.

Analyst Coverage

Lipocine Inc. is covered by the following analysts.

Firm Analyst
Canaccord Genuity, Inc. Dewey Steadman
Phone: 212-389-8128
Ladenburg Thalmann & Co. Inc. Matt Kaplan
Phone: 212-409-2000
Zacks Investment Research, Inc. John Vandermosten
Phone: 312-265-9588
HC Wainwright Oren Livnat
Roth Capital TBD


Please note that any opinions, estimates or forecasts regarding Lipocine Inc.'s performance made by these analysts are theirs alone and do not represent opinions, forecasts or predictions of Lipocine Inc. or its management. Lipocine Inc. does not by its reference above or distribution imply its endorsement of or concurrence with such information, conclusions or recommendations.